- Home
- BCDA vs FTFT Comparison
BCDA vs FTFT Comparison
Compare BCDA & FTFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- FTFT
- Stock Information
- Founded
- BCDA N/A
- FTFT N/A
- Country
- BCDA United States
- FTFT United States
- Employees
- BCDA N/A
- FTFT N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- FTFT Business Services
- Sector
- BCDA Health Care
- FTFT Consumer Discretionary
- Exchange
- BCDA Nasdaq
- FTFT Nasdaq
- Market Cap
- BCDA 7.9M
- FTFT 8.7M
- IPO Year
- BCDA N/A
- FTFT N/A
- Fundamental
- Price
- BCDA $2.05
- FTFT $0.30
- Analyst Decision
- BCDA Strong Buy
- FTFT
- Analyst Count
- BCDA 1
- FTFT 0
- Target Price
- BCDA $25.00
- FTFT N/A
- AVG Volume (30 Days)
- BCDA 31.3K
- FTFT 406.2K
- Earning Date
- BCDA 11-13-2024
- FTFT 11-19-2024
- Dividend Yield
- BCDA N/A
- FTFT N/A
- EPS Growth
- BCDA N/A
- FTFT N/A
- EPS
- BCDA N/A
- FTFT N/A
- Revenue
- BCDA $71,000.00
- FTFT $18,543,659.00
- Revenue This Year
- BCDA N/A
- FTFT N/A
- Revenue Next Year
- BCDA N/A
- FTFT N/A
- P/E Ratio
- BCDA N/A
- FTFT N/A
- Revenue Growth
- BCDA N/A
- FTFT N/A
- 52 Week Low
- BCDA $1.84
- FTFT $0.26
- 52 Week High
- BCDA $10.80
- FTFT $2.60
- Technical
- Relative Strength Index (RSI)
- BCDA 42.16
- FTFT 40.23
- Support Level
- BCDA $2.00
- FTFT $0.26
- Resistance Level
- BCDA $2.14
- FTFT $0.52
- Average True Range (ATR)
- BCDA 0.16
- FTFT 0.05
- MACD
- BCDA -0.00
- FTFT -0.01
- Stochastic Oscillator
- BCDA 15.91
- FTFT 21.50
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and cryptocurrency mining farm in the U.S. The company's reportable segments include the Supply chain financing/trading segment which generates key revenue, and the Asset management service segment.